Veronique D
- Novartis (NYSE:NVS) on Tuesday said that Coartem (artemether-lumefantrine) Baby has been approved by Swissmedic as the first malaria medicine for newborns and young infants.
- The new treatment, also known as Riamet Baby in some countries, was developed in collaboration with Medicines for
